Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Intel Boosts Malaysia Operations with Additional RM860 Million Investment 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Dollar Slips as Weak U.S. Manufacturing Data Increases Pressure for Fed Rate Cuts 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure 
South Korea Inflation Edges Up in November as Food and Service Costs Climb 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
